Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)

NCT06261125 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

RADIATION: Stereotactic body radiotherapy
DRUG: Adebrelimab
DRUG: Lenvatinib

Sponsor

Mian XI